

해외 바이오의약품 임상 현황 ('24년 4월 3주)

한국바이오의약품협회, 2024.04.23.

※ ClinicalTrials.gov에 등록된 국가별 바이오의약품 임상시험 목록(병용요법 포함)을 한국바이오의약품협회에서 주간 업데이트하여 제공합니다.
URL을 클릭하시면 세부 정보 페이지로 연결됩니다.
- 출처: ClinicalTrials.gov
- 모니터링 기간: 2024.04.15.~2024.04.21.
- 주간 업데이트 제공국가 : 미국, 유럽(영국, 프랑스, 독일), 중국, 일본

○ 미국 13건					
NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT04129515	NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis	Device: NovoTTF-200A Drug: Pembrolizumab	Brown University NovoCure Ltd.	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT04129515
NCT06316297	Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne	Biological: Acne mRNA vaccine Other: Placebo	Sanofi Pasteur, a Sanofi Company Sanofi	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06316297
NCT06343376	Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies	Procedure: Biopsy Procedure: Biospecimen Collection Procedure: Bone Marrow Aspiration Procedure: Bone Marrow Biopsy Procedure: Computed Tomography Drug: Cyclophosphamide Procedure: Echocardiography Biological: EGFRt/19-28z/IL-12 CAR T-lymphocytes Drug: Fludarabine Phosphate Procedure: Leukapheresis Procedure: Multigated Acquisition Scan Procedure: Positron Emission Tomography	Roswell Park Cancer Institute	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06343376
NCT06271252	A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study	Drug: OriCAR-017	OriCell Therapeutics Co., Ltd.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06271252
NCT06202066	Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Tumors	Procedure: Biospecimen Collection Procedure: Computed Tomography Biological: Incomplete Freund's Adjuvant Procedure: Magnetic Resonance Imaging Biological: Sargramostim Biological: SVN53-67/M57-KLH Peptide Vaccine Drug: Temozolomide	Roswell Park Cancer Institute	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06202066
NCT05741164	Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer	Procedure: Biopsy Procedure: Biospecimen Collection Procedure: Computed Tomography Biological: Pembrolizumab Drug: Propranolol Other: Questionnaire Administration	Roswell Park Cancer Institute	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05741164
NCT06236438	Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)	Drug: Livmoniplimab Drug: Budigalimab Drug: Pembrolizumab Drug: Pemetrexed Drug: Cisplatin Drug: Carboplatin	AbbVie	Phase 2 Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06236438
NCT06227546	MGC018 in Patients With Relapsed or Refractory Extensive-Stage Small-Cell Lung Cancer	Drug: MGC018	Georgetown University MacroGenics	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06227546
NCT06340854	A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetes	Drug: Insulin icodec Drug: Insulin glargine	Novo Nordisk A/S	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06340854

해외 바이오의약품 임상 현황 ('24년 4월 3주)

한국바이오의약품협회, 2024.04.23.

○ 미국 13건					
NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06377566	A Study of BV-AVD in People With Bulky Hodgkin Lymphoma	Drug: Brentuximab vedotin Drug: Doxorubicin Drug: Vinblastine Drug: Dacarbazine Drug: Pembrolizumab Drug: Gemcitabine Drug: Vinorelbine Diagnostic Test: FDG-PET/CT scan	Memorial Sloan Kettering Cancer Center Seagen Inc.	Phase 2	https://clinicaltrials.gov/study/NCT06377566
NCT06373380	A Study of HB-202/HB-201 in People With Human Papilloma Virus 16-Positive Head and Neck Squamous Cell Cancer (HPV 16+ HNSCC)	Drug: HB-200 Other: Placebo	Memorial Sloan Kettering Cancer Center Hookipa Biotech GmbH Naveris	Phase 2	https://clinicaltrials.gov/study/NCT06373380
NCT05748197	A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia	Biological: ADCLEC.syn1 CAR T cells Drug: Conditioning chemotherapy	Memorial Sloan Kettering Cancer Center Takeda	Phase 1	https://clinicaltrials.gov/study/NCT05748197
NCT05096481	PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma	Biological: PEP-CMV Drug: Temozolomide Biological: Tetanus Diphtheria Vaccine	Nationwide Children's Hospital	Phase 2	https://clinicaltrials.gov/study/NCT05096481

○ 영국 1건					
NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06355583	Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) Trial	Drug: EBX-102 Drug: Placebo	Imperial College London	Phase 2	https://clinicaltrials.gov/study/NCT06355583

○ 프랑스 1건					
NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06353022	Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma	Drug: Teclistamab Drug: Talquetamab Drug: Lenalidomide Drug: Bortezomib Drug: Daratumumab Drug: Dexamethasone	Nantes University Hospital Janssen Pharmaceutica	Phase 2	https://clinicaltrials.gov/study/NCT06353022

○ 독일 2건					
NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06123468	Study Evaluating Treatment of Sacituzumab-govitecan for Patients With Metastatic Esophagogastric Adenocarcinoma	Drug: Sacituzumab govitecan	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest Gilead Sciences	Phase 1 Phase 2	https://clinicaltrials.gov/study/NCT06123468
NCT06340854	A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetes	Drug: Insulin icodec Drug: Insulin glargine	Novo Nordisk A/S	Phase 3	https://clinicaltrials.gov/study/NCT06340854

○ 중국 11건					
NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06217757	Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC	Radiation: Low-dose radiotherapy Drug: Etoposide Drug: Cisplatin Drug: Sugemalimab Drug: Olaparib	Sichuan University	Phase 1 Phase 2	https://clinicaltrials.gov/study/NCT06217757
NCT05924776	Plasmodium Immunotherapy for Advanced Ovarian Cancer	Biological: Plasmodium immunotherapy	CAS Lamvac (Guangzhou) Biomedical Technology Co., Ltd. The Third Affiliated Hospital of Southern Medical University CAS Lamvac Biotech Co., Ltd.	Phase 2 Phase 3	https://clinicaltrials.gov/study/NCT05924776

해외 바이오의약품 임상 현황 ('24년 4월 3주)

한국바이오의약품협회, 2024.04.23.

○ 중국 11건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05906524	KD6001 in Combination With Anti-PD-1 Antibody±Bevacizumab in Patients With Advanced HCC and Other Solid Tumors	Drug: KD6001 Drug: Tislelizumab Drug: Bevacizumab	Shanghai Kanda Biotechnology Co., Ltd.	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05906524
NCT06373991	A Study to Evaluate the Safety and Efficacy of ATHENA CAR-T in Subjects With Systemic Lupus Erythematosus	Biological: ATHENA CAR-T Drug: Fludarabine Drug: Cyclophosphamide	EdiGene Inc. The First Affiliated Hospital of Henan University of Science and Technology Changping Laboratory	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06373991
NCT06364384	Radical Synchronous Chemoradiotherapy With DDP/5-FU and PD-1 for Non-metastatic Rectal Squamous Cell Carcinoma	Combination Product: PD-1 and CRT	Sixth Affiliated Hospital, Sun Yat-sen University	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06364384
NCT06340230	SHR-A1811 Alone or in Combination With Adebrelimab as Neoadjuvant Treatment in ER Positive/HER2 Low Breast Cancer	Drug: SHR-A1811 Injection + Adebrelimab Injection Drug: SHR-A1811 Injection	Shengjing Hospital Jiangsu HengRui Medicine Co., Ltd.	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06340230
NCT06078306	CD19CD22 CAR-T Therapy in Patients With High-Risk B Acute Lymphoblastic Leukemia (B-ALL).	Drug: Azacitidine Injection Drug: Venetoclax Drug: CD19CD22 CAR-T	The First Affiliated Hospital of Soochow University	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06078306
NCT06376331	Washed Microbiota Transplantation for Attention-deficit/Hyperactivity Disorder	Drug: washed microbiota transplantation	The Second Hospital of Nanjing Medical University SIR RUN RUN hospital of Nanjing Medical University	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06376331
NCT06323525	TCR Reserved and Power3 Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma	Biological: TCR reserved and Power3 gene knock-out allogeneic CD19-targeting CAR-T cell (ATHENA-2 CAR-T) Drug: Fludarabine Drug: Cyclophosphamide	Chinese PLA General Hospital	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06323525
NCT06331156	A Study on the Immune Response and Safety of Inactivated Poliovirus Vaccine (IPV) When Co-administered With Human Rotavirus (HRV) Porcine Circovirus (PCV)-Free Vaccine in Healthy Chinese Infants	Combination Product: HRV PCV-free Combination Product: IPV	GlaxoSmithKline	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06331156
NCT06364904	An Phase III Study, Multicenter, Randomized Controlled Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma.	Drug: Tislelizumab, Cisplatin, Gemcitabine and Trilaciclib Drug: Tislelizumab, Cisplatin, Gemcitabine	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06364904

○ 일본 3건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06297616	A Study of LY3841136 in Japanese Participants With Obesity or Overweight	Drug: LY3841136 Drug: Placebo	Eli Lilly and Company	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06297616
NCT06317311	A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer	Biological: Dostarlimab Drug: Carboplatin Drug: Paclitaxel	GlaxoSmithKline	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06317311
NCT06340854	A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetes	Drug: Insulin icodec Drug: Insulin glargine	Novo Nordisk A/S	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06340854